Drugs in early clinical development for the treatment of osteosarcoma
2017
Heymann, Marie-Françoise | Brown, Hannah, K | Heymann, Dominique | Department of Oncology and Metabolism [Sheffield, UK] ; University of Sheffield [Sheffield] | Equipe LIGUE Nationale Contre le Cancer 2012 ; Physiopathologie des Adaptations Nutritionnelles (PhAN) ; Institut National de la Recherche Agronomique (INRA)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE) ; Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Recherche Agronomique (INRA)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE) ; Université de Nantes (UN)-Université de Nantes (UN) | European Associated Laboratory [Sheffield, UK] (Sarcoma Research Unit) ; University of Sheffield [Sheffield] | This study was supported by the Ligue Contre le Cancer, FR (research project: Equipe LIGUE 2012) and the Bone Cancer Research Trust, UK (research project number 144681).
International audience
Afficher plus [+] Moins [-]anglais. Introduction: Osteosarcomas are the main malignant primary bone tumours found in children and young adults. Conventional treatment is based on diagnosis and resection surgery, combined with polychemotherapy. This is a protocol that was established in the 1970s. Unfortunately, this therapeutic approach has reached a plateau of efficacy and the patient survival rate has not improved in the last four decades. New therapeutic approaches are thus required to improve the prognosis for osteosar-coma patients. Areas covered: From the databases available and published scientific literature, the present review gives an overview of the drugs currently in early clinical development for the treatment of osteosar-coma. For each drug, a short description is given of the relevant scientific data supporting its development. Expert opinion: Multidrug targeted approaches are set to emerge, given the heterogeneity of osteo-sarcoma subtypes and the multitude of therapeutic responses. The key role played by the microenvir-onment in the disease increases the number of therapeutic targets (such as macrophages or osteoclasts), as well as the master proteins that control cell proliferation or cell death. Ongoing phase I/II trials are important steps, not only for identifying new therapies with greater safety and efficacy, but also for better defining the role played by the microenvironment in the pathogenesis of osteosarcoma.
Afficher plus [+] Moins [-]Mots clés AGROVOC
Informations bibliographiques
Cette notice bibliographique a été fournie par Institut national de la recherche agronomique
Découvrez la collection de ce fournisseur de données dans AGRIS